For the third time in about a month, another major pharmaceutical competitor has released a new COVID cure – in this case, it was Regeneron’s long-awaited COVID antibody cocktail – which purportedly cut infection risk by 81.6% (not quite as much as Pfizer’s pill, but more than Merck’s pill)
Another Regeneron antibody product has been in the works for a long time and was memorably used on an experimental basis when President Trump was sickened with the virus and brought to Walter Reed for treatment. At the time, some scientists slammed the use of the Regeneron drug. But a lot more research has been conducted over the last year.